Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis

Rheumatology International

Volumn 35, Issue 6, 2015, Pages 1021-1025

  Hernández Flórez, Diana ^a   Valor, Lara ^a   de la Torre, Inmaculada ^a   Nieto, Juan Carlos ^a   Martínez Estupiñán, Lina ^a   González, Carlos ^a   López Longo, Francisco Javier ^a   Monteagudo, Indalecio ^a   Garrido, Jesús ^b   Naredo, Esperanza ^a   Carreño, Luis ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Agreement; Ankylosing spondylitis (AS); Anti drug antibodies (ADA); Anti TNF; Enzyme linked immunosorbent assay (ELISA); Infliximab (IFX)

Indexed keywords

C REACTIVE PROTEIN; DRUG ANTIBODY; HLA B27 ANTIGEN; INFLIXIMAB; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; BLOOD; COMPARATIVE STUDY; DRUG MONITORING; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; SPONDYLITIS, ANKYLOSING;

ADULT; CROSS-SECTIONAL STUDIES; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SPONDYLITIS, ANKYLOSING;

EID: 84939418121     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-014-3180-2     Document Type: Article

References (25)

1. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(3):iii8–iii18
2. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41(1):58–67
3. van der Horst-Bruinsma IE, Clegg DO, Dijkmans BA (2002) Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs. Clin Exp Rheumatol 20(6 Suppl 28):S67–S70
4. de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66(9):1252–1254
5. Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E (2010) Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 65(5):657–661. doi:10.1111/j.1398-9995.2009.02280.x
6. Nestorov I (2005) Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl 74:13–18
7. Garces S, Demengeot J, Benito-Garcia E (2013) The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72(12):1947–1955. doi:10.1136/annrheumdis-2012-202220
8. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9):1552–1563
9. Aarden L, Ruuls SR, Wolbink G (2008) Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 20(4):431–435. doi:10.1016/j.coi.2008.06.011
10. Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, Aarden LA, Rispens T (2011) Differential effect of drug interference in immunogenicity assays. J Immunol Methods 372(1–2):196–203
11. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(6):1451–1459
12. Maser EA, Villela R, Silverberg MS, Greenberg GR (2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol 4(10):1248–1254
13. Svenson M, Geborek P, Saxne T, Bendtzen K (2007) Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 46(12):1828–1834. doi:10.1093/rheumatology/kem261
14. Mulleman D, Meric JC, Paintaud G, Ducourau E, Magdelaine-Beuzelin C, Valat JP, Goupille P (2009) Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. Arthritis Res Ther 11(6):R178. doi:10.1186/ar2867
15. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR (2010) Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 59(1):49–54
16. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368
17. Vincent W, Weir J (2012) Statistics in Kinesiology, 4th edn. Champaign, IL
18. Fleiss JL (1971) Measuring nominal scale agreement among many raters. Psychol Bull 76(5):378
19. Cohen J (1968) Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 70(4):213–220
20. Plasencia C, Pascual-Salcedo D, Nuno L, Bonilla G, Villalba A, Peiteado D, Diez J, Nagore D, del Agua AR, Moral R, Martin-Mola E, Balsa A (2012) Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis 71(12):1955–1960. doi:10.1136/annrheumdis-2011-200828
21. Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van der Veer E, Houtman PM, Griep EN, Limburg PC, Kallenberg CG, Wolbink GJ, Brouwer E (2010) The formation of autoantibodies and antibodies to TNF-alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(5):661–668
22. Levesque BG, Greenberg GR, Zou G, Sandborn WJ, Singh S, Hauenstein S, Ohrmund L, Wong CJ, Stitt LW, Shackelton LM, King D, Lockton S, Ducharme J, Feagan BG (2014) A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn’s disease. Aliment Pharmacol Ther 39(10):1126–1135
23. Steenholdt C, Ainsworth MA, Tovey M, Klausen TW, Thomsen OO, Brynskov J, Bendtzen K (2013) Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn’s disease. Ther Drug Monit 35(4):530–538
24. Vande Casteele N, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, van der Kleij D, Gils A, Dijkstra G (2012) Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 36(8):765–771
25. Ruiz-Arguello B, del Agua AR, Torres N, Monasterio A, Martinez A, Nagore D (2013) Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 51(12):e287–e289